Kongfei Li

  • Citations Per Year
Learn More
The methylation inhibitor 5-Aza-2′-deoxycytidine (decitabine, DAC) has a great therapeutic value for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). But decitabine monotherapy was associated with a relatively low rate of complete remission in AML and MDS. We aimed to investigate the effect of several anti-leukemia drugs in combination with(More)
Dear Editor, Acute promyelocytic leukemia (APL) is now considered a curable leukemia that is particularly sensitive to alltrans retinoic acid (ATRA) [1–3]. ider(17)(q10)t(15;17) (q22;q21) is a rare variant cytogenetic abnormality among APL patients, and its prognostic significance is still controversial [4–10]. We describe here a 58-year-old female with APL(More)
OBJECTIVE To investigate the expression level and regulation mechanism of miR-720 as well as the association of miR-720 expression with leukemia biological characteristics. METHODS Expression and promoter methylation of miR-720 were determined by quantitive PCR and pyrosequencing in 38 patients with AML and 20 normal controls. Lentivirous-mediated miR-702(More)
Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the potential of LB100, a small-molecule protein phosphatase 2 A (PP2A)(More)
  • 1